Schering-Plough (SGP) and Merck (MRK) Announce Withdrawal of NDA for Loratadine/Montelukast Combination Tablet
More News related to MRK
- Merck Discontinues Development of Investigational Medicine Taranabant for Obesity
- SAFE-BioPharma Announces Fast, Innovative Identity Proofing Procedure
- Merck to Hold Third-Quarter 2008 Sales and Earnings Conference Call on Oct. 22
- ISENTRESS(TM) (raltegravir) Awarded Prix Galien USA Top Honor
- Merck & Co., Inc. and Japan Tobacco Inc. Sign Licensing Agreement for Novel Osteoanabolic Drug Candidate to Treat Osteoporosis
More News related to SGP
- David Moenning's Daily State of the Markets: 10/03
- Notable Analyst Rating Changes 10/3: COST, CS, CSX, URBN Upgraded; CMI, WAG, SGP, SCG Downgraded
- Merrill Lynch Downgrades Schering-Plough (SGP) to Underperform
- Schering-Plough Schedules Conference Call and Webcast for 2008 Third Quarter Earnings
- U.S. Pet Owners can Double the Impact of Vaccinations to Help Reduce Rabies in Africa, Save Lives
Schering-Plough Corp. (NYSE: SGP) and Merck & Co., Inc. (NYSE: MRK) announce the withdrawal of the New Drug Application (NDA) for the loratadine/montelukast combination tablet.
The companies also terminated the Schering-Plough/Merck Pharmaceuticals respiratory joint venture, which was formed in May 2000 to develop and market a fixed-combination product that would combine loratadine and montelukast. This action has no impact on the business of the Merck/Schering-Plough cholesterol joint venture.
The U.S. Food and Drug Administration (FDA) issued on April 25, 2008 a not-approvable letter for the proposed fixed-dose combination of loratadine and montelukast.
As a result of the termination of the respiratory joint venture, Schering- Plough expects to receive payments totaling $105 million from Merck as specified in the joint venture agreements which Schering-Plough will recognize over the remaining three quarters of 2008.[SM]
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
